Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer

Background EML4-ALK is a distinct molecular entity that is highly sensitive to ALK tyrosine kinase inhibitors (TKIs). Immune checkpoint inhibitors (ICIs) have not proved efficacy in ALK-positive non-small cell lung cancer so far. In this study, we performed a mouse clinical trial using EML4-ALK tran...

Full description

Saved in:
Bibliographic Details
Main Authors: Sung Sook Lee, Byoung Chul Cho, Hye Ryun Kim, Kyoung-Ho Pyo, Sun Min Lim, Hyo Sup Shim, Jae Hwan Kim, Min Hee Hong, Chae-Won Park, Ha-Ni Jo, Mi-Ran Yun, Dohee Kim, Chun-Feng Xin, Wongeun Lee, Bianca Gheorghiu, Mi Jang
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000970.full
Tags: Add Tag
No Tags, Be the first to tag this record!